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CASE REPORT

Acute Lymphoblastic Leukemia in a Child with Fanconi's Anaemia
Naureen Mushtaq1, Rabia Wali2, Zehra Fadoo1 and Ali Faisal Saleem1

ABSTRACT
Fanconi anaemia (FA) is an autosomal recessive inherited disorder with progressive bone marrow failure, associated
congenital malformation and solid and haematological malignancies. Acute myeloid leukemia is the commonest
haematological malignancy followed by myelodysplastic syndrome in children with FA. FA transformed into acute
lymphoblastic leukemia (ALL) is a rare phenomenon and one of the rarest haematological malignancies associated with
this disorder. We are reporting a 13 years old girl with FA and positive chromosomal breakage. She required regular blood
product transfusion. She was planned for haematopoietic stem cell transplantation (HSCT) but the sibling-matched donor
was found to have chromosomal breaks as well. Later on, her peripheral smear showed blast cell. Bone marrow showed
pre-B ALL. She was started on chemotherapy but died shortly due to complications of the treatment. For this rare condition
conservative management is indeed essential, however, safe and appropriate chemotherapy regimen is needed.
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INTRODUCTION

CASE REPORT

Fanconi anaemia (FA) is a constitutional pancytopenia
of childhood with mostly autosomal recessive
inheritance with diverse clinical heterogeneity including
congenital malformations, progressive bone marrow
failure and high propensity for cancer in long-term,
mostly solid tumours and carcinoma of head, neck and
upper oesophagus followed by carcinoma of vulva
and/or anus and lower oesophagus; however, it is also
associated with acute leukemia with marked predisposition with acute myeloid leukemia (AML) and rarely
acute lymphoblastic leukemia (ALL).1,2 Myelodysplastic
syndromes may follow clinically overt aplastic anaemia
or develop without a detectable antecedent.3 The
incidence of AML or myelodysplastic syndrome in FA is
approximately 15%.4 All patients have underlying
abnormal chromosome fragility seen in metaphase
preparations which was enhanced by adding clastogenic
agents such as diepoxybutane.4,5 Growth hormone (GH)
therapy for FA can also lead to ALL.6 Sensitivity to DNA
damaging agents limits therapy in patients with FA;
however, severe toxicity and marrow aplasia without
haematological recovery has also been described in the
literature.7

The patient was a 13 years old girl at presentation to the
haematology and oncology clinic with prolonged history
of blood transfusion since last 6 years. She had no
previous records available. However, she was on
regular once fortnightly packed cell transfusion and
weekly platelet transfusion. On examination, she was
short statured with microcephaly, having triangular
facies and areas of hyperpigmentation. There was no
organomegaly or lymphadenopathy. She had six siblings
and they were healthy when she presented to us.
Because of FA suspicion her laboratory workup was
done. Her complete blood count showed pancytopenia,
with < 20% cellularity of bone marrow on trephine biopsy
and chromosomal breaks was positive. She was kept on
supportive management and planned for haematopoietic
stem cell transplantation (HSCT). Her human leukocyte
antigen (HLA) typing along with her siblings was also
done. Unfortunately, the patient's HLA matched donor
was also positive for chromosomal breaks.

FA transformation into ALL is a rare phenomenon. There
are very few case reports in the literature. Here we
present this rare entity of FA with ALL.
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Two months later she presented in emergency with
jaundice, abdominal pain, swelling of feet and abdominal
distension. Her laboratory work-up was positive for
Hepatitis B virus active infection and with the
consultation with infectious diseases expert she was
started on anti-hepatitis B therapy. Later on, her general
condition improved.
After 2 months she again presented to the emergency
room with intermittent fever and worsening pallor. Her
examination showed marked hepatosplenomegaly.
Laboratory work-up revealed pancytopenia with 63%
blast cells; Bone marrow flow-cytometry was consistent
with Pre-B ALL.
Her clinical status deteriorated rapidly and she became
vitally unstable. She was planned for four- drug induction
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therapy (vincristine, L-asparaginase, prednisolone and
daunorubicin) as per ALL protocol, but because of her
severe diastolic dysfunction daunorubicin was omitted
from the chemotherapy. She succumbed to infection and
died on the 7th day of induction therapy with
septicaemia; however, none of her cultures were
positive.

Table I: Studies with FA cases along with their haematological
malignancies distribution.
Studies

Fanconi anaemia (FA) is a genetic disorder characterized
by congenital abnormalities, cancer predisposition, and
progressive pancytopenia. The cellular phenotype of FA
is characterized by increased sensitivity to DNA crosslinking or alkylating agents that block DNA replication
and RNA transcription.8
FA children typically present in the first decade of life on
recognition of aplastic anaemia.1 The classic features of
FA consist of thumb and radial absence malformations;
less obvious features include a deeper cleft between the
first two digits. The gold standard for FA quantify
chromosomal breakage in cells exposed to cross-linking
agents to which FA cells are hypersensitive.2
FA patients have a very high risk of developing
progressive bone marrow failure along with an increased
risk of future long-term malignancies. The most frequent
malignancy in FA is acute myeloid leukemia (AML) with
a cumulative incidence of 33% by 40 years of age.8
This patient developed ALL which is rare, but possible
acute leukemia in FA. The FA-related leukemias differ
from leukemia in the general population in several
important ways.9 In FA patients, 94% of the acute
leukemias are myeloid and only 6% are lymphoid
compared with 84% of the acute leukemias being
lymphoid in general paediatric population. The age
distribution for acute leukemia in FA was normally
distributed around a mode of 14 years; however, in the
general population in which the incidence of AML is
higher in infants, it was declined to around age 10, and
then rises slightly in the late teens.2 The age of this
patient was 13 years when she diagnosed as ALL.
Cancer risk assessment was done for FA. Table I
showed the three studies with their haematological
frequency of malignancies. First was a literature review
of 1300 reported cases of FA from 1927 to 2001;10
second was of 754 FA patients from the International
Fanconi Anaemia Registry (IFAR) ascertained from
1982 to 2001,8 while the third was a cross-sectional
study of 145 North American patients during 2000.11 It
was seen that the cumulative incidence of ALL in FA was
0.5% (12/2200 patients).
There is dearth of knowledge of ALL in FA and to the
best of the authors' knowledge there has been no case
reported of FA with ALL from our region. A Dutch study
reported a 7 years old boy with FA who developed preleukemia and was not treated because of the known

Haematological malignancies
AML

Alter BP (2003) (10)

DISCUSSION

Total cases
of Fanconi
anaemia

MDS

ALL

Total
haematological
malignancies

1301

109

89

07

Rosenberg PS (2003) (11)

145

09

23

–

32

Kutler DI (2003) (8)

754

60

53

05

120

2200

–

–

Total cases

++ ALL incidence 0.5 (12/2200)
Abbreviations: AML = Acute myeloid leukemia;
ALL = Acute lymphoblastic lymphoma;

12++

205

–

MDS = Myelodysplastic syndrome;

complications of cytostatic in FA and the bad prognosis
and later on he died. Another study from Poland,
reported 2 children with Fanconi anaemia who
developed acute lymphoblastic leukemia at the age of 4
and 12 years.12
The treatment of FA with ALL is very scanty in literature.
Borriello reported the case of a patient affected by T-cell
ALL without the clinical features specific for FA.3
Because of severe chemotherapy toxicity, occurring with
several episodes of marrow aplasia leading to lifethreatening infections, a suspicion of FA diagnosis led us
to perform the chromosomal breakage study using the
diepoxybutane (DEB) test, which was found to be
positive. The patient was treated on lines of T-cell ALL
induction therapy comprising of vincristine, L-asparaginase,
anthracylines, steroids and cyclophosphamide.3
The index patient was also planned for four-drug
induction therapy with vincristine, daunorubicin, steroids
and L-asparaginase; but as patient had sub-optimal
cardiac function anthracyline was omitted for the time
being. The patient died on 7th day of her induction
therapy due to septicaemia.
In conclusion, the existence of ALL in patients with FA is
rarely reported and further work is needed to determine
the appropriate chemotherapy regimen in these
patients.
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